Is serputinib/serpatinib included in medical insurance?
Selpercatinib/Selpercatinib has not yet been included in the national medical insurance. The domestically marketed original drug is sold under the name Seputinib. Since it has been on the market for a short time in China, patients are not yet able to enjoy reimbursement from the national medical insurance. If you can enroll in medical insurance, the specific reimbursement policies may vary depending on the region and changes in medical insurance policies. It is recommended to consult the local medical insurance department or relevant medical institutions to obtain the most accurate information.
Seputinib is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor developed by Eli Lilly and Company for the treatment of cancers containing RET alterations. Eli Lilly and Company recently received approval from the U.S. Food and Drug Administration (FDA) for the treatment of RET fusion-positive non-small cell lung cancer, RET fusion-positive thyroid cancer and RET-mutated medullary thyroid cancer based on results from the Phase I/II LIBRETTO-001 trial. Seputinib has a good safety profile, but is associated with hepatotoxicity, hypertension, QT interval prolongation, bleeding events, risk of impaired wound healing, and embryo-fetal toxicity; some patients may also be allergic to seputinib.
The domestic marketed saputiniboriginal drug, specifications80mg*56 capsules may cost more than 10,000 yuan per box. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)